FI117319B - Gepiroonikoostumuksia - Google Patents

Gepiroonikoostumuksia Download PDF

Info

Publication number
FI117319B
FI117319B FI954154A FI954154A FI117319B FI 117319 B FI117319 B FI 117319B FI 954154 A FI954154 A FI 954154A FI 954154 A FI954154 A FI 954154A FI 117319 B FI117319 B FI 117319B
Authority
FI
Finland
Prior art keywords
gepirone
dosage form
composition according
weight
magnesium stearate
Prior art date
Application number
FI954154A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI954154A0 (fi
FI954154A (fi
Inventor
Claude E Gallian
Stephen T David
Joseph C H Chou
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of FI954154A0 publication Critical patent/FI954154A0/fi
Publication of FI954154A publication Critical patent/FI954154A/fi
Application granted granted Critical
Publication of FI117319B publication Critical patent/FI117319B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Electroluminescent Light Sources (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI954154A 1994-09-06 1995-09-05 Gepiroonikoostumuksia FI117319B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/301,281 US5478572A (en) 1994-09-06 1994-09-06 Gepirone dosage form
US30128194 1994-09-06

Publications (3)

Publication Number Publication Date
FI954154A0 FI954154A0 (fi) 1995-09-05
FI954154A FI954154A (fi) 1996-03-07
FI117319B true FI117319B (fi) 2006-09-15

Family

ID=23162703

Family Applications (1)

Application Number Title Priority Date Filing Date
FI954154A FI117319B (fi) 1994-09-06 1995-09-05 Gepiroonikoostumuksia

Country Status (25)

Country Link
US (1) US5478572A (cs)
EP (1) EP0700680B1 (cs)
JP (1) JP4540756B2 (cs)
KR (1) KR100380806B1 (cs)
CN (1) CN1096858C (cs)
AT (1) ATE186462T1 (cs)
AU (1) AU702282B2 (cs)
CA (1) CA2157323C (cs)
CY (1) CY2222B1 (cs)
CZ (1) CZ286417B6 (cs)
DE (1) DE69513254T2 (cs)
DK (1) DK0700680T3 (cs)
ES (1) ES2142432T3 (cs)
FI (1) FI117319B (cs)
GR (1) GR3032598T3 (cs)
HK (1) HK1014666A1 (cs)
HU (1) HU227339B1 (cs)
IL (1) IL114984A (cs)
NO (1) NO307814B1 (cs)
NZ (1) NZ272855A (cs)
PL (1) PL180691B1 (cs)
RU (1) RU2155044C2 (cs)
SG (1) SG30436A1 (cs)
TW (1) TW445152B (cs)
ZA (1) ZA957144B (cs)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215507A1 (en) * 1996-03-25 2003-11-20 Wyeth Extended release formulation
US20060062843A1 (en) * 1996-03-25 2006-03-23 Wyeth Extended release formulation
US20040023948A1 (en) * 1997-03-24 2004-02-05 Green Richard David Fast-dispersing dosage form containing 5-HT1 agonists
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
US5895663A (en) * 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
CN100367965C (zh) * 1999-12-20 2008-02-13 法布瑞－克雷默制药有限公司 吉吡隆代谢物在制备改善哺乳动物不良心理状态的组合物上的应用
US6534507B1 (en) * 1999-12-20 2003-03-18 Fabre-Kramer Pharmaceuticals, Inc. Methods for treating psychological disorders using bioactive metabolites of gepirone
HUP0401021A2 (hu) * 2000-12-08 2004-09-28 Akzo Nobel N.V. Gepiront tartalmazó gyógyászati készítmény orális beadásra
MXPA03009391A (es) 2001-05-01 2004-01-29 Pfizer Prod Inc METODO PARA FABRICAR UNA COMPOSICIoN FARMACEUTICA DE DOSIS BAJA.
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
US20030152621A1 (en) * 2001-11-21 2003-08-14 Egberink J. G. J. Pharmaceutical formulation of gepirone for oral administration
TW200306866A (en) * 2002-05-07 2003-12-01 Akzo Nobel Nv A method to improve surface properties of pharmaceutical tablets
EP1545469A1 (en) * 2002-09-24 2005-06-29 Akzo Nobel N.V. Method to improve pharmaceutical tablets having a matrix of cellulose ether
RS51934B (en) 2003-08-08 2012-02-29 Biovail Laboratories International Srl. BUPROPION HYDROCHLORIDE TABLE WITH MODIFIED RELEASE
AR048112A1 (es) * 2004-03-25 2006-03-29 Solvay Pharm Bv Derivados de 1-(2h-1-benzopiran-2-on-8-il)-piperazina para el tratamiento de dolor
AR049478A1 (es) * 2004-03-25 2006-08-09 Solvay Pharm Bv Un procedimiento para la preparacion de 3-amino-8-(1-piperazinil)-2h-1-benzopiran-2-ona. sales e hidratos y composiciones farmaceuticas.
US7799273B2 (en) 2004-05-06 2010-09-21 Smp Logic Systems Llc Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes
US7444197B2 (en) 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
JP2008506668A (ja) * 2004-07-15 2008-03-06 ソルベイ・フアーマシユーチカルズ・ベー・ブイ ３−アミノ−８−（１−ピペラジニル）−２ｈ−１−ベンゾピラン−２−オンの長時間放出型調製物
US20060013874A1 (en) * 2004-07-15 2006-01-19 Solvay Pharmaceuticals B.V. Extended release formulation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one
US20060099267A1 (en) * 2004-11-05 2006-05-11 Fabre-Kramer Pharmaceuticals, Inc. High-dosage extended-release formulation of gepirone
MX2007005368A (es) * 2004-11-05 2007-09-11 Fabre Kramer Holdings Inc Formulacion con liberacion prolongada de dosis alta de gepirona.
PL2168585T3 (pl) * 2005-06-09 2012-05-31 Euro Celtique Sa Kompozycje farmaceutyczne steroidów neuroaktywnych i ich zastosowania

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
GB1405088A (en) * 1971-06-03 1975-09-03 Mundipharma Ag Slow release formulation
US3965256A (en) * 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4357469A (en) * 1979-06-14 1982-11-02 Forest Laboratories, Inc. Carrier base material for prolonged release therapeutic compositions
US4309406A (en) * 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4248856A (en) * 1979-07-10 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4248858A (en) * 1979-08-09 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4547358A (en) * 1980-05-06 1985-10-15 Mead Johnson & Company Sustained release tablet containing at least 95 percent theophylline
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
US4690824A (en) * 1983-07-07 1987-09-01 Redi-Rowell, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US4695591A (en) * 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
US4771053A (en) * 1987-03-02 1988-09-13 Bristol-Myers Company Method for alleviation of primary depressive disorders
US4782060A (en) * 1987-07-29 1988-11-01 Bristol-Myers Company Gepirone for alleviation of panic disorders
SE8703881D0 (sv) * 1987-10-08 1987-10-08 Haessle Ab New pharmaceutical preparation
SE8704097D0 (sv) * 1987-10-22 1987-10-22 Astra Ab Oral formulation of buspirone and salts thereof
US5106849A (en) * 1988-05-24 1992-04-21 American Home Products Corporation Use of aryl- and heteroaryl piperazinyl carboxamides in the treatment of various central nervous system disorders
US5096908A (en) * 1990-05-04 1992-03-17 Eli Lilly And Company Method of inhibiting gastric acid secretion
US5189179A (en) * 1990-08-29 1993-02-23 Merrell Dow Pharmaceuticals Inc. Serotonin 5ht1a agonists
US5124346A (en) * 1991-04-23 1992-06-23 Pfizer Inc. Synergistic combinations in the treatment of anxiety
US5169638A (en) * 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
US5292766A (en) * 1992-03-25 1994-03-08 Eli Lilly And Company Method for improving primary memory and/or learning
US5378846A (en) * 1993-06-11 1995-01-03 Russian-American Institute For New Drug Development 1,2,3,4-tetrahydropyrrolo-[1,2-a]-pyrazine derivatives

Also Published As

Publication number Publication date
KR100380806B1 (ko) 2003-07-10
HU9502599D0 (en) 1995-11-28
PL310298A1 (en) 1996-03-18
JP4540756B2 (ja) 2010-09-08
CY2222B1 (en) 2003-04-18
IL114984A0 (en) 1995-12-08
CN1128142A (zh) 1996-08-07
ES2142432T3 (es) 2000-04-16
US5478572A (en) 1995-12-26
CZ227595A3 (en) 1996-03-13
EP0700680A1 (en) 1996-03-13
NO953212D0 (no) 1995-08-16
SG30436A1 (en) 1996-06-01
ATE186462T1 (de) 1999-11-15
HK1014666A1 (en) 1999-09-30
DK0700680T3 (da) 2000-05-01
FI954154A0 (fi) 1995-09-05
HUT73182A (en) 1996-06-28
TW445152B (en) 2001-07-11
HU227339B1 (en) 2011-04-28
EP0700680B1 (en) 1999-11-10
NZ272855A (en) 1997-05-26
RU2155044C2 (ru) 2000-08-27
NO953212L (no) 1996-03-07
IL114984A (en) 1999-10-28
DE69513254T2 (de) 2000-06-15
CN1096858C (zh) 2002-12-25
CA2157323A1 (en) 1996-03-07
CZ286417B6 (en) 2000-04-12
FI954154A (fi) 1996-03-07
ZA957144B (en) 1996-03-26
NO307814B1 (no) 2000-06-05
AU702282B2 (en) 1999-02-18
DE69513254D1 (de) 1999-12-16
PL180691B1 (en) 2001-03-30
AU3043895A (en) 1996-03-21
GR3032598T3 (en) 2000-05-31
KR960010007A (ko) 1996-04-20
JPH08183736A (ja) 1996-07-16
CA2157323C (en) 2004-01-20

Similar Documents

Publication Publication Date Title
FI117319B (fi) Gepiroonikoostumuksia
EP1468679B1 (en) Controlled release formulation containing tramadol
EP1767206B1 (en) Solid oral dosage forms comprising valsartan and hydrochlorothiazide
US8318203B2 (en) Form of administration of racecadotril
JP2015131853A (ja) リルピビリンＨＣｌおよびフマル酸テノホビルジソプロキシルを含有する治療用組成物
ZA200501541B (en) Bicifadine formulation
HU226956B1 (en) Matrix tablet for sustained release of trimetazidine after oral administration
JP2011507973A (ja) アムロジピンとバルサルタンとの医薬組成物
US20080008751A1 (en) Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof
CN101808630A (zh) 阿利吉仑的盖仑制剂
EP1079834B1 (en) Stable compositions comprising levosimendan and alginic acid
CN110913843B (zh) 药物组合物
ZA200005632B (en) Controlled release peroral compositions of levosimendan.
US20030119882A1 (en) Solid pharmaceutical composition containing torasemide
EP1889629B1 (en) Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof
US20040192706A1 (en) Method and compositions for treating anxiety
MX2007005368A (es) Formulacion con liberacion prolongada de dosis alta de gepirona.

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 117319

Country of ref document: FI

MM Patent lapsed